Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 14/20 | 0.75 |
| ▸ | CYP1A1 | P04798 | 13/20 | 0.75 |
| ▸ | CYP1B1 | Q16678 | 13/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.62 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.62 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.62 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.62 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.62 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL714242 | 1.00 | CYP1A2 (0.75) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL29575647 | 1.00 | CYP1A2 (0.75) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL1426024 | 0.93 | CYP1A2 (0.70) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL29915985 | 0.93 | CYP1A2 (0.70) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL1426026 | 0.93 | CYP1A2 (0.70) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL24017227 | 0.88 | CYP1A2 (0.58) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL5877571 | 0.87 | CYP1A1 (0.69) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL2121298 | 0.87 | CYP1A1 (0.69) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL26924044 | 0.86 | CYP1A2 (0.84) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL25706432 | 0.86 | CYP1A2 (1.00) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376441-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | UNIV YONSEI IACF (KR) | 2025-12-11 | — | — | US | disclosed |
| US-20220226340-A1 | CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER | Facio Intellectual Property B.V. (NL) | 2022-07-21 | — | — | US | disclosed |
| EP-3982955-A1 | CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER | Facio Intellectual Property B.V. (NL) | 2022-04-20 | — | — | EP | disclosed |
| US-20210289794-A1 | COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-23 | — | — | US | disclosed |
| WO-2020249717-A1 | CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER | Facio Intellectual Property B.V. (NL) | 2020-12-17 | — | — | WO | disclosed |
| US-20200190024-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2020-06-18 | — | — | US | disclosed |
| CN-110279680-A | A kind of medical composition and its use | 有联生技股份有限公司 | 2019-09-27 | — | — | CN | disclosed |
| CN-106220507-A | Compound with (1E,6E) -1, 7-bis- (3, 4-dimethoxyphenyl) -4, 4-disubstituted hepta-1, 6-diene-3, 5-dione structural framework and application thereof | 有联生技股份有限公司 | 2016-12-14 | — | — | CN | disclosed |
| CN-104755076-A | Compounds having (1E,6E) -1, 7-bis- (3, 4-dimethoxyphenyl) -4, 4-disubstituted hepta-1, 6-diene-3, 5-dione structural skeleton, their biological activity and use thereof | ANDROSCIENCE CORP | 2015-07-01 | — | — | CN | disclosed |
| CN-100502846-C | 3,4,5,-substituted benzyl ethylene derivatives and their preparation and use | ZHEJIANG HAIZHENG PHARMACEUTIC (CN) | 2009-06-24 | — | — | CN | disclosed |
| EP-1070726-B1 | ASPARTYL DIPEPTIDE ESTER DERIVATIVES AND SWEETENERS | AJINOMOTO KK (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-6566557-B2 | Oxidation of a phenylpropane compound | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2003-05-20 | — | — | US | disclosed |
| EP-1045842-B1 | METHODS OF USE AND COMPOSITIONS FOR BENZYLIDENE- AND CINNAMYLIDENE-ANABASEINES | UNIV FLORIDA (US) | 2003-05-14 | — | — | EP | disclosed |
| US-6548096-B1 | Aspartyl dipeptide ester derivatives and sweeteners | AJINOMOTO CO., INC. (JP) | 2003-04-15 | — | — | US | disclosed |
| US-20020133045-A1 | Process for the preparation of substituted trans-cinnamaldehyde, a natural yellow dye, from phenylpropane derivatives | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2002-09-19 | — | — | US | disclosed |
| WO-2002072709-A1 | A PROCESS FOR THE PREPARATION OF SUBSTITUTED TRANS-CINNAMALDEHYDE, A NATURAL YELLOW DYE, FROM PHENYLPROPANE DERIVATIVES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2002-09-19 | — | — | WO | disclosed |
| EP-1070726-A1 | ASPARTYL DIPEPTIDE ESTER DERIVATIVES AND SWEETENERS | Ajinomoto Co., Inc. (JP) | 2001-01-24 | — | — | EP | disclosed |
| EP-1045842-A2 | METHODS OF USE AND COMPOSITIONS FOR BENZYLIDENE- AND CINNAMYLIDENE-ANABASEINES | University of Florida (US) | 2000-10-25 | — | — | EP | disclosed |
| US-5977144-A | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines | UNIVERSITY OF FLORIDA (US) | 1999-11-02 | — | — | US | disclosed |
| WO-1999010338-A2 | BENZYLIDENE- AND CINNAMYLIDENE-ANABASEINES AS NEURONAL NICOTINIC ALPHA-7 RECEPTOR AGONISTS | UNIVERSITY OF FLORIDA (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226340-A1 | CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER | CSNK1A1, CSNK1G3, CSNK1G1 | CYP1A2 4828/4885CYP1A1 4753/4885CYP1B1 4758/4885 |
| US-20200190024-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | PRKAA1, PRKAA2, PRKAG1 | CYP1A2 4142/4885CYP1A1 4083/4885CYP1B1 4227/4885 |
| US-20250376441-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | PRKAA1, PRKAA2, PRKAG1 | CYP1A2 4142/4885CYP1A1 4083/4885CYP1B1 4227/4885 |
| US-20020133045-A1 | Process for the preparation of substituted trans-cinnamaldehyde, a natural yellow dye, from phenylpropane derivatives | CBR3, DDT, DHODH | CYP1A2 1016/4885CYP1A1 881/4885CYP1B1 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.